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Biodistribution studies showed that injection into the lymph 
node delivered antigen more efficiently to subcutaneous 
lymph nodes than subcutaneous injection.  Conclusions: As 
intralymphatic immunisation induced more than 10-fold 
higher IgG2a responses with 100-fold lower allergen doses 
than subcutaneous immunisation, this approach should al-
low to reduce both the number of allergen injections as well 
as the allergen dose, improving both efficacy and safety of 
SIT.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Allergy treatment with corticosteroids and antihista-
mines can efficiently ameliorate IgE-mediated symptoms 
but cannot cure the disease and cannot stop its progres-
sion. The only treatment with a long-lasting effect is aller-
gen-specific immunotherapy (SIT), classically performed 
by repeated subcutaneous allergen injections. Despite the 
high efficacy of SIT and despite its recommendation as a 
first-line therapy  [1] , less than 5% of allergic patients 
choose to undergo SIT, mainly due to the long duration of 
the treatment (3–5 years), the high number of injections 
required (30–70) and the risk of adverse allergic reactions 
 [2] . Therefore, there is a high interest in improving current 
methods of SIT. Numerous studies have investigated new 
strategies to optimise the allergen molecules  [3–5] , the ad-
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 Abstract 
 Background: IgE-mediated allergy can be treated by subcu-
taneous allergen-specific immunotherapy (SIT). However, 
the percentage of allergic patients undergoing SIT is low, 
mainly due to the long duration of the therapy and the risk 
of severe systemic allergic reactions associated with the al-
lergen administration. To improve the safety and attractive-
ness of SIT for patients, alternative routes of allergen admin-
istration are being explored, such as sub-lingual or oral 
administration.  Methods: The present study evaluated di-
rect intralymphatic allergen administration as a means to 
enhance SIT with bee venom and cat fur allergens in mice. 
Allergen-specific antibody and T-cell responses were anal-
ysed by ELISA and flow cytometry. The therapeutic potential 
of intralymphatic immunisation in sensitised mice was anal-
ysed using an anaphylaxis model.  Results: Direct injection 
of the major bee venom allergen phospholipase A 2 or the 
major cat fur allergen Fel d 1 into inguinal lymph nodes en-
hanced allergen-specific IgG and T-cell responses when 
compared with subcutaneous injections. Moreover, only in-
tralymphatic immunisation stimulated the production of 
the Th1-dependent subclass IgG2a, which is associated with 
improved protection against allergen-induced anaphylaxis. 
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juvants used  [6–8] , the dosage form  [9–11] , as well as the 
route of allergen administration  [12–14] . 
 Immune responses are induced in secondary lym-
phoid organs, where professional antigen-presenting cells 
present antigenic epitopes to lymphocytes, and where T- 
and B-cell interactions take place. If antigens stay outside 
organised lymphoid tissues, then even large amounts of 
antigens can be ignored by the immune system  [15, 16] . 
Therefore, antigen localisation is an important regulator 
of the immune response. Accordingly, direct administra-
tion of antigens into lymph nodes should be a more effi-
cient route of immunisation. We have already demon-
strated this for the administration of naked DNA vac-
cines  [17] , major histocompatibility complex class I 
binding peptide vaccines  [18] and tumour cells  [19] . In 
the present study, we compared subcutaneous with direct 
intralymphatic administration of allergens in mice as a 
means for improving the efficacy of SIT. 
 Methods 
 Immunisation Protocols 
 Female CBA mice (6–8 weeks old; Harlan, Horst, The Nether-
lands) were immunised 3 times with 2-week intervals by injection 
with the major bee venom allergen phospholipase A 2 (PLA 2 ; n = 
5; Sigma-Aldrich, Buchs, Switzerland) or recombinant Fel d 1
(n = 4), the major cat allergen. Fel d 1 was cloned into the pQE30 
expression vector (Qiagen, Hilden, Germany) as an N-terminal 
[His] 6 -tag fusion protein, produced in  Escherichia coli and puri-
fied as described  [20] . The lipopolysaccharide content of Fel d 1 
was 1.27 ng/mg of protein, as determined by the Limulus amoe-
bocyte lysate assay. Different doses of the allergens were mixed 
with aluminium hydroxide (Alhydrogel 3%; Brenntag Biosector, 
Fredrikssund, Denmark) and saline 1 h before intralymphatic in-
jection into the inguinal lymph node  [18] or subcutaneously at the 
base of the tail. The doses of aluminium hydroxide were 90 and 
450   g, for intralymphatic and subcutaneous injections, respec-
tively, and the injection volumes were 10 and 50   l. Serum was 
prepared from tail vein blood drawn at different time points and 
frozen at –20 ° C until analysed by ELISA.
 Alternatively, the 2 routes of administration were tested in a 
therapeutic model in CBA mice that were first sensitised with cat 
fur allergen extract (Stallergènes, Fresnes, France) by 6-weekly 
intraperitoneal injections. The allergen extract (1   g/dose) was 
adsorbed to aluminium hydroxide (900   g/dose) and injected in 
a volume of 100   l. Two weeks after the last sensitisation injec-
tion, groups of 4 mice each were desensitised with 1   g Fel d 1 by 
intralymphatic or subcutaneous injections as described above. As 
positive control, a group of sensitised but not treated mice was 
used, while naïve mice were used as negative controls. For the in-
duction of anaphylaxis, all 4 groups of mice were challenged, 3 
weeks after the last desensitisation injection, with 30   g of cat fur 
allergen extract in saline (50   l i.p.), and the body temperature 
was measured with a calibrated digital thermometer before and 
30 min after the challenge. All animal experiments were approved 
by and performed according to guidelines from the Swiss veteri-
nary authorities.
 Antibody Measurements 
 For antibody detection, 96-well microtitre plates (Nunc Maxi-
sorb, Basel, Switzerland) were coated with 1   g/ml cat fur aller-
gen extract (Stallergènes) or 5   g/ml of PLA 2 (Sigma) in carbonate 
buffer and incubated overnight at 4 ° C. After blocking the plates 
with 2.5% non-fat dry milk in PBS-0.05% Tween-20 (PBSTM), se-
rial dilutions of individual sera in PBSTM were added to the plates 
and incubated for 2h. Then plates were incubated with 1   g/ml 
biotinylated goat anti-mouse IgG1 or IgG2a (BD Pharmingen, 
San Diego, Calif., USA) in PBSTM, followed by incubation with a 
1: 1,000 dilution of streptavidin-conjugated horseradish peroxi-
dase (BD Pharmingen). In the last step, plates were incubated with 
the enzyme substrate 2,2-azino-bis-(3-ethylbenzothiazoline-6-
sulfonic acid) di-ammonium salt (Sigma-Aldrich) in 1  M sodium 
dihydrogen phosphate. The absorption was read at 405 nm on a 
Model 550 Microplate reader (Bio-Rad, Hercules, Calif., USA). 
Unless otherwise specified, all incubations were done at room 
temperature and were intercepted with PBST washes.
 For detection of PLA 2 -specific IgE antibodies, plates were 
coated with 2   g/ml of anti-mouse IgE capture antibody (BD 
Pharmingen). As secondary reagent for binding to mouse serum, 
an in-house biotinylated PLA 2 was used at 3   g/ml.
 For detection of Fel d 1-specific IgE antibodies, plates were 
coated with anti-mouse IgE (BD Pharmingen) at 2   g/ml and 
then incubated for 2 h with serum samples from immunised mice. 
Subsequently, rFel d 1 was added at 0.6   M and the plates incu-
bated for another 90 min. For detection, anti-Fel d 1-biotin anti-
body (Indoor Biotechnology, Warminster, UK) at 1: 1,000 dilution 
(90 min) was used.
 Flow Cytometry and Cytokine Secretion Assay  
 One week after the last injection of allergen, spleens were iso-
lated and single-cell suspensions were prepared. For intracellular 
staining of interferon (IFN)-  , red blood cell-free splenocytes 1 
 ! 10 6 were stimulated overnight with 0.5   g/ml ionomycin and 
5   g/ml heat-denatured PLA 2 , the last 4 h in the presence of 
brefeldin A. After blocking of Fc receptors (anti-CD16/CD32), the 
splenocytes were fixed in PBS/PFA 1% for 10 min and permeabi-
lised in PBS/NP40 0.1% for 3 min. Thereafter, the cells were 
stained with FITC-labelled antibodies specific for CD8 or CD4, 
as well as PE-labelled anti-CD44 and antigen-presenting cell-la-
belled anti-IFN-  for 30 min at 4 ° C. All antibodies were pur-
chased from BD Pharmingen.
 For analysis of cytokine secretion by ELISA, triplicates of 8  ! 
10 5 cells were cultured with 10   g/ml LoTox Fel d 1 from Indoor 
Biotechnology or left unstimulated in 200   l of IMDM supple-
mented with 5% FCS, sodium pyruvate,  L -glutamine, penicillin 
and streptomycin. The cytokines secreted in the supernatant were 
measured using the DuoSet ELISA from R&D Systems (Abing-
don, UK) after 20 h (IL-2) or after 72 h (IL-4, IL-10 and IFN-  ). 
The detection limit for IFN-  and IL-10 was 30 pg/ml and for IL-
2 and IL-4 15 pg/ml.
 Biodistribution 
 To compare the relative biodistribution of intralymphatically 
and subcutaneously administered proteins, CBA mice were in-
jected with  99m Tc pertechnetate-labelled human immunoglobu-
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lin (TechneScan  HIG) from Mallinckrodt Medical B.V., Petten, 
The Netherlands; the half life of  99m Tc is approximately 6 h. The 
radioactive protein was injected intralymphatically in the ingui-
nal lymph node or subcutaneously in the inguinal region at
3 MBq per dose. Four animals each were euthanised 90 min and 
17 h after injection. Lungs, spleen, liver and inguinal lymph nodes 
were dissected and analysed directly in a Cobra II gamma counter 
(Packard Bioscience, Dreieich, Germany). The absolute distribu-
tion to each organ was expressed as radioactive count per min-
utes.
 Statistics 
 Differences between independent groups were tested by non-
parametric statistical analysis. Data were presented as means  8 
standard error and compared using a 2-sided independent Mann-
Whitney U test or Kruskal-Wallis one-way analysis of variance 
with Dunn’s multiple comparison test. The significance level was 
set at 5%.
 Results 
 Intralymphatic Immunisation with Bee Venom PLA 2 
Enhanced Immune Responses 
 To asses the influence of the route of administration 
on the immunogenicity of allergens, mice were immun-
ised thrice with 2-week intervals using either 0.1 or 10   g 
of the bee venom major allergen PLA 2 either by subcuta-
neous or intralymphatic injections. As illustrated in  fig-
ure 1 a, a dose as small as 0.1   g PLA 2 was sufficient to 
induce high PLA 2 -specific IgG2a titers by intralymphat-
ic injection. In order to induce comparable titers by sub-
cuntaneous injections, 10   g of PLA 2 were necessary. 
Similar differences were observed for IgG1. Neither in-
tralymphatic nor subcutaneous injections induced sig-
nificant IgE titres.
 In a similar experiment, 7 days after the last immuni-
sation with 1   g PLA 2 , splenocytes were re-stimulated in 
vitro for analysis of IFN-  secretion by flow cytometry. 
As illustrated in  figure 1 b, intralymphatic injections elic-
ited significantly higher CD8 T-cell responses than sub-
cutaneous injections.
 Intralymphatic Immunisation Also Enhanced 
Immune Responses to Cat Fur Allergen Fel d 1 
 The following experiments aimed at expanding the 
above observations to another allergen. The perennial 
major cat fur allergen Fel d 1 was intralymphatically in-
jected into mice at doses of 0.1 and 1   g and compared 
with the subcutaneous injection of 10   g Fel d 1. Compa-
rably high IgG1 levels were induced in all 3 groups of 
mice, independent of the route of administration or the 
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 Fig. 1. Bee venom PLA 2 -specific antibody and IFN-  secretion. 
Mice were immunised thrice with 0.1 or 10   g bee venom PLA 2 
adsorbed on aluminium hydroxide by intralymphatic (IL) or sub-
cutaneous (SC) injections.  a Mice were bled at indicated time 
points, and the titres of sera analysed for PLA 2 -specific IgG2a, 
IgG1 and IgE are illustrated.  b Seven days after the last of 3 injec-
tions with 1   g PLA 2 , the splenocytes were re-stimulated in vitro 
and the IFN-  secretion analysed by flow cytometry. The results 
illustrate the percentage of IFN-  -producing CD4 or CD8 T cells 
that are also positive for CD44. p values indicated are obtained by 
Mann-Whitney analysis. All data are illustrated as means + SEM 
(n = 5).  
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dose ( fig. 2 ). However, only mice that received Fel d 1 by 
intralymphatic injection produced IgG2a, and 0.1   g was 
sufficient to stimulate a significant response. Titres then 
remained constant for at least 8 weeks after the last injec-
tion.
 Seven days after 3 immunisations with Fel d 1, spleno-
cytes were re-stimulated in vitro with Fel d 1 for analysis 
of cytokine secretion by ELISA. The secretion of IL-2 was 
determined in the supernatants after 20 h, while IL-4, IL-
10 and IFN-  were measured after 72 h ( fig. 3 ). The cyto-
kine secretion was typically higher in cultured cells from 
mice that had been immunised by intralymphatic aller-
gen administration, and the differences between stimu-
lated and non-stimulated cells only reached statistical 
significance in the intralymphatically injected group. 
 Immunotherapy by Intralymphatic Fel d 1 
Administration Enhanced Protection against 
Anaphylaxis 
 Mice were sensitised using repeated low-dose intraper-
itoneal injections of cat fur allergen extract, inducing sig-
nificant levels of allergen-specific serum IgE and IgG1, 
but no detectable IgG2a (data not shown). These allergic 
mice were subsequently desensitised with Fel d 1, by 3 in-
tralymphatic or subcutaneous injections with 2-week in-
tervals. Again, a stronger IgG2a response was observed 
after intralymphatic allergen administration than after 
the subcutaneous injections ( fig. 4 a). Three weeks after 
completion of immunotherapy, mice were intraperitone-
ally challenged with a high dose of cat fur allergen extract 
and subsequently monitored for anaphylaxis, which in 
mice manifests as a drop in body temperature. As illus-
trated in  figure 4 b, immunotherapy by intralymphatic ad-
ministration of Fel d 1 induced significant protection 
against anaphylactic temperature drop (p = 0.048). In 
contrast, subcutaneous immunotherapy was not suffi-
cient to protect sensitised mice against the temperature 
drop.
 Intralymphatic Injections Caused Accumulation of 
Allergen in Lymphoid Tissue 
 One possible explanation to the observed benefit of 
intralymphatic over subcutaneous immunotherapy could 
be an inefficient drainage to secondary lymphatic tissue 
after subcutaneous injections, i.e. intralymphatic injec-
tions deliver more antigen to the site of immune response 
induction. This difference in allergen dose available for 
stimulation of allergen-specific lymphocytes may also 
lead to an increase in the Th1 immune responses ob-
served after intralymphatic allergen administration. 
Hence, to analyse the fate of an injected protein as a func-
tion of the administration route, mice received either in-
tralymphatic or subcutaneous injections of a human im-
munoglobulin labelled with radioactive technetium. As 
illustrated in  figure 5 , analysis of the radioactivity in dif-
ferent organs 90 min after injection revealed that more 
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 Fig. 2. Cat allergen-specific IgG1, IgG2a and IgE antibodies (Abs) 
measured by ELISA. Mice were immunised thrice, intralymphat-
ically (IL) with 0.1 or 1   g of Fel d 1 or subcutaneously (SC) with 
10   g Fel d 1. The sera were analysed after 2, 5 and 8 weeks of the 
last injection. The data from the last time point are illustrated and 
expressed as means  8 SEM (n = 4). One representative out of 2 
independent experiments is shown.  Fig. 3. Cytokine secretion assay. Groups of 4 mice were immun-
ised thrice with 1   g of Fel d 1 intralymphatically (IL) or subcu-
taneously (SC), and the splenocytes were analysed for secretion of 
different cytokines after  in vitro re-stimulation with 10   g/ml of 
Fel d 1. The cytokine concentrations in supernatants of stimu-
lated (open bars) or unstimulated cultures (filled bars) are shown 
as measured by ELISA. Statistical differences were analysed by 
Kruskal-Wallis with a Dunn’s post test of variance ( * p  ! 0.05 and 
 * * p  ! 0.01) (n = 4). 
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radioactivity was measured in inguinal lymph nodes af-
ter intralymphatic administration than after subcutane-
ous injection (p  ! 0.05). In contrast, subcutaneously ad-
ministered protein drained more rapidly to the liver (p  ! 
0.05). Seventeen hours after injection, radioactivity was 
generally reduced in all organs, but again, approximately 
10 times more radioactivity could be detected in the in-
guinal lymph nodes of mice injected by the intralym-
phatic route than by the subcutaneous route (p  ! 0.05). 
 Discussion 
 IgE-mediated allergies, such as allergic rhinoconjunc-
tivitis and asthma, have become highly prevalent, affect-
ing up to 35% of the population in industrialised coun-
tries  [21–23] . The best long-lasting treatment available for 
these patients is SIT  [24] . However, the major problems of 
current SIT regimes are the long-term commitment of 
the patient, the high treatment costs, and the significant 
risk of allergic adverse reactions associated with the al-
lergen administration  [2] . One approach for improving 
SIT focuses on the route of allergen administration. In 
this respect, sublingual immunotherapy, in which the al-
lergen is given as soluble tablets or drops, and local nasal 
immunotherapy have proven promising and especially 
attractive for patients  [1, 25–27] . However, the treatment 
duration of sublingual immunotherapy and nasal SIT re-
mains similar to that of current subcutaneous SIT  [28] , 
and the required allergen doses are at least 50–100 times 
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 Fig. 4. SIT and test of anaphylaxis. Groups of 4 mice were sensi-
tised against Fel d 1 by intraperitoneal injections of cat fur aller-
gen extract and then treated by intralymphatic (IL) or subcutane-
ous (SC) injections of recombinant Fel d 1. Three weeks after the 
last SIT injection, mice were challenged with 30   g of cat fur al-
lergen extract. The negative control (ctrl) group contained naive 
mice, while the positive control was a group of sensitised mice that 
did not receive immunotherapy. Two weeks after the last SIT in-
jection, mice were bled and IgG2a levels were determined ( a ). The 
body temperature was measured before and 30 min after the chal-
lenge ( b ). The groups were compared by Kruskal-Wallis with a 
Dunn’s post test of variance ( * p  ! 0.05).  
 Fig. 5. Biodistribution of intralymphatically (IL) and subcutane-
ously (SC) injected protein. Groups of 4 mice were injected with 
 99m Tc-labelled human immunoglobulin directly into an inguinal 
lymph node (open bars) or subcutaneously in the inguinal region 
(filled bars). After 90 min and after 17 h, the mice were euthanised, 
and the inguinal lymph nodes (LN), the spleen, the lungs as well 
as all liver lobes were isolated and immediately assayed for radio-
active gamma decoy (cpm). Statistical differences are indicated 
when  * p  ! 0.05, as analysed by the Mann-Whitney U test. 
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higher than the dose needed for subcutaneous immuni-
sation  [29] .
 The results presented in the current study show that 
direct intralymphatic injection enhances immunogenic-
ity of allergens as compared with the classical subcutane-
ous SIT route of administration. These results are in line 
with already published data showing enhanced immuno-
genicity of intralymphatic injection using plasmid DNA 
vaccines  [17] , major histocompatibility complex class I 
binding peptides  [18] and tumour cells  [28] . Other groups 
have also demonstrated enhanced efficacy by targeted 
lymph node immunisation with immunostimulatory 
complexes  [30] , bacteriophages  [31] , a recombinant sim-
ian immunodeficiency virus vaccine  [32] , and a canary 
pox virus-based cancer vaccine  [33] . In addition, intra-
lymphatic administration required less than 1% antigen 
 [17] or immune stimulatory molecules  [34] to induce po-
tent cytotoxic T-cell immune responses than did sub-
cutaneous antigen administration. In the present study, 
intralymphatic immunisation was shown to stimulate 
humoral immune responses comparable with that of sub-
cutaneous SIT, but using only 1% of the allergen dose. 
Moreover, while subcutaneous SIT induced mostly IgG1 
antibodies, intralymphatic allergen administration stim-
ulated both Th1- and Th2-associated antibody subclass-
es. The enhanced humoral immune responses observed 
after intralymphatic immunisation were consistent with 
a general increase in the secretion of cytokines after re-
stimulation of the lymphocytes in vitro. 
 The reason why the intralymphatic route of immuni-
sation was more efficient than subcutaneous allergen ad-
ministration in stimulating immune responses, especial-
ly of the Th1 type, is most likely a matter of dose and lo-
calisation, as proposed by the geographical concept of 
immune reactivity that emphasises the importance of an-
tigen localisation  [15] . As conventional T- and B-cell re-
sponses can only be induced in organised lymphoid tis-
sues, the direct injection of antigens into subcutaneous 
lymph nodes would obviously facilitate the stimulation of 
stronger immune responses. As demonstrated in the bio-
distribution experiments using radioactively labelled 
proteins, only a few percentage of the subcutaneously in-
jected material drained and remained in the lymphatic 
tissue (spleen and inguinal lymph nodes), while most of 
the material ended up in the liver. In contrast, after intra-
lymphatic administration, the entire allergen dose is 
available for antigen presentation in the lymph node. 
This, and the fact that high antigen doses favour Th1-like 
immune responses  [35, 36] , could explain why efficient 
lymphatic targeting of the allergen is important for the 
stimulation of protective immune responses in SIT. 
 As lower therapeutic doses are required to induce 
comparably strong immune responses, intralymphatic 
immunotherapy should improve the safety of immuno-
therapy and reduce the risk of local and systemic allergic 
side effects. Although the presence of mast cells as well as 
basophils has been described in the lymph node  [37] , we 
found excellent local tolerance of allergen injection into 
inguinal lymph nodes in our clinical trial  [38] .
 Recently, intralymphatic immunotherapy has been 
tested in humans for the treatment of both grass pollen 
and bee venom allergies, demonstrating the clinical fea-
sibility and efficacy of this approach  [38] . The injection 
into subcutaneous lymph nodes has also been applied in 
the treatment of other diseases, such as cancer  [33] . 
 In conclusion, the intralymphatic route of administra-
tion may represent a promising method to increase the 
efficacy of SIT, to reduce the required allergen dose and 
number of injections, and to reduce the risk of adverse 
events as compared with conventional subcutaneous im-
munotherapy. 
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